AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
SAN DIEGO, Dec. 21, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced yesterday that they will merge with and become a fully owned subsidiary of the JSR Corporation, headquartered in Tokyo, Japan. The merger produces a fully integrated suite of innovative solutions to support researchers through every stage of drug and diagnostic development – from early research through manufacturing.
The strategic merger integrates Crown Bioscience’s leading translational technology platform providing drug target validation, efficacy testing and patient response characterization with JSR’s in vitro diagnostic (IVD) solutions, GMP manufacturing capabilities and worldwide distribution networks.
“We are excited to join the JSR family of companies through this innovation-driven strategic partnership,” said Dr. Jean-Pierre Wery, Crown Bioscience’s Chief Executive Officer. “Crown Bioscience’s core competencies in preclinical and translational research combined with JSR’s global footprint, diagnostic solutions and manufacturing capabilities will provide a fully integrated solution to help biopharmaceutical companies get drugs and diagnostics to market more efficiently.”
The completion of the merger is expected to close before the end of the second quarter of 2018.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
